Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Share-based Compensation (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Share-based Compensation for 11 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation changed N/A year-over-year to $3.4 million, compared with a TTM value of $6.2 million through Dec 2025, up 813.58%, and an annual FY2025 reading of $4.1 million, up 817.61% over the prior year.
  • Share-based Compensation was $3.4 million for Q4 2025 at Abvc Biopharma, up from $1.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.7 million in Q1 2022 and bottomed at -$592229.0 in Q3 2023.
  • Average Share-based Compensation over 5 years is $1.0 million, with a median of $350740.0 recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 634220.0% in 2021, then plummeted 362.35% in 2023.
  • Year by year, Share-based Compensation stood at $4.4 million in 2021, then crashed by 85.13% to $651365.0 in 2022, then dropped by 17.61% to $536648.0 in 2023, then crashed by 57.94% to $225740.0 in 2024, then skyrocketed by 1419.59% to $3.4 million in 2025.
  • Business Quant data shows Share-based Compensation for ABVC at $3.4 million in Q4 2025, $1.1 million in Q3 2025, and $1.6 million in Q2 2025.